Colchicine Attenuates Inflammation Beyond the Inflammasome in Chronic Coronary Artery Disease
Circulation, 2020
Opstal T., Hoogeveen R., Fiolet A., Silvis M., The S., Bax W., de Kleijn D., Mosterd A., Stroes E., Cornel J.
| Disease area | Application area | Sample type | Products |
|---|---|---|---|
CVD | Pathophysiology | Serum |  Olink Target 96 |
Abstract
Inflammation plays a crucial role in the progression of atherosclerosis. The COLCOT trial recently showed cardiovascular benefit of treatment with colchicine. Colchicine is an established anti-inflammatory drug, which attenuates NLRP3 inflammasome-mediated crystal-induced inflammation present in gout due to uric acid crystals, and in atherosclerosis due to cholesterol crystals.2 In addition, colchicine may inhibit phagocytosis and neutrophil activity. The exact impact of colchicine in human atherosclerosis remains unclear. In the present study, we studied the anti-inflammatory potential of colchicine in patients with chronic coronary artery disease by comparing serum samples before and after 30 days of colchicine treatment using targeted proteomics.